Sumitomo Mitsui Trust Group Inc. Lowers Position in Johnson & Johnson $JNJ

Key Points

• Sumitomo Mitsui Trust Group decreased its Johnson & Johnson stake by 3.8% (selling 233,153 shares) to 5,946,335 shares worth about $1.23 billion, making JNJ 0.7% of its portfolio and its 17th-largest holding.
• Johnson & Johnson beat Q1 estimates (revenue $24.06B, EPS $2.70), raised FY‑2026 guidance (11.45–11.65 EPS) and hiked the quarterly dividend to $1.34, prompting multiple analyst price-target upgrades and a consensus "Moderate Buy" (~$248).
• Insiders sold 30,142 shares in the past three months (about $7.36M), including large sales by EVPs Timothy Schmid and Vanessa Broadhurst, leaving insiders with 0.16% ownership.

Sumitomo Mitsui Trust Group Inc. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,946,335 shares of the company's stock after selling 233,153 shares during the period. Johnson & Johnson comprises 0.7% of Sumitomo Mitsui Trust Group Inc.'s portfolio, making the stock its 17th largest holding. Sumitomo Mitsui Trust Group Inc. owned 0.25% of Johnson & Johnson worth $1,230,594,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. United Bank grew its position in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after buying an additional 4,876 shares during the period. Sivia Capital Partners LLC grew its position in Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock worth $896,000 after buying an additional 692 shares during the period. Wealth Group Ltd. grew its position in Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after buying an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. grew its position in Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after buying an additional 6,584 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 22,623 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and raised full‑year outlook: JNJ reported $24.06B revenue and $2.70 EPS (above estimates) and raised FY‑2026 sales and EPS guidance, highlighting strong oncology and MedTech growth. Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
• Positive Sentiment: Dividend hike reinforces income thesis: the board raised the quarterly payout to $1.34 (64th consecutive annual increase), which supports yield-focused investors. Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
• Positive Sentiment: Broker support rising: several firms raised price targets (Goldman Sachs, Wells Fargo, Raymond James, JPMorgan, Bernstein, Leerink), reflecting analyst confidence after the quarter and creating potential upside. These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results
• Neutral Sentiment: Investor access / upcoming presentation: management will host a fireside chat at the Bank of America Healthcare Conference (May 12) — a chance to get more color on 2026 growth drivers. Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
• Neutral Sentiment: Full transcripts and analyst takes are available — useful if you’re re‑evaluating forecasts or positioning before the conference. Johnson & Johnson NYSE: JNJ Q1 2026 Earnings Call Transcript
• Negative Sentiment: Market reaction / profit‑taking: despite the beat, the stock slipped as some investors viewed the sales guidance as modest and digested mixed signals — early selling pressure reflects profit‑taking and short‑term disappointment. Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance
• Negative Sentiment: Legacy product headwinds: a steep decline in Stelara sales was noted by management and media, which offsets some of the new‑product gains and contributed to concerns about near‑term revenue mix and cash‑flow dynamics. J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Analysts Set New Price Targets

Several brokerages have weighed in on JNJ. Weiss Ratings restated a "buy (b)" rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Wolfe Research upped their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an "outperform" rating in a research report on Monday, January 5th. Barclays upped their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Wednesday. UBS Group restated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $248.17.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $238.59 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a market cap of $574.67 billion, a P/E ratio of 27.58, a PEG ratio of 2.40 and a beta of 0.34. The company has a 50-day moving average of $241.67 and a two-hundred day moving average of $216.53. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.75%. The firm's quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson's dividend payout ratio (DPR) is presently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.